BRAF and hereditary disease: In particular, future study is needed on whether the introduction of our case selection is possible to omit BRAF V600E mutation or MLH1 promoter methylation analysis and whether step-by-step explanations given to complement patients’ lack of knowledge about genetic diseases may have a negative impact, such as causing further anxiety to patients.